EuroBiotech: More Articles of Note

Newspapers

> Shares in Ose Immunotherapeutics crashed after it halted enrollment in a phase 3 trial. Ose hit pause on the trial of Tedopi in non-small cell lung cancer at the request of an independent data monitoring committee. Treatment of patients already enrolled in the trial is continuing. Release 

> Bavarian Nordic posted data from a phase 2 trial of its universal RSV vaccine. The 421-subject trial linked the vaccine to significant increases in antibodies. Bavarian Nordic plans to discuss the data with regulators with a view to running a phase 3 trial during the 2019 to 2020 RSV season. Statement

> A phase 3 trial of remimazolam met its primary endpoint. The trial linked the ultra-short-acting sedative and anesthetic to a significantly higher rate of procedural success than midazolam in patients undergoing bronchoscopy. Germany’s Paion licensed the drug to Switzerland’s Cosmo Pharmaceutical. Cosmo now has the data from two phase 3 trials it needs to file for FDA approval. Release

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Servier teamed up with Transgene to explore the use of viral vectorization technology in the production of allogeneic CAR-T drugs. The collaboration will make use of Transgene’s viral vector collection. Statement (PDF)

> Heptares entered into two collaborations. The British biotech followed Amgen, Bristol-Myers Squibb, Eli Lilly, Genentech, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis and Sanofi by striking a deal with PeptiDream. One day earlier, Heptares had unveiled a collaboration with the New York University School of Medicine. Release I More

> VarmX raised seed funding. The Dutch biotech will use the cash to fund development of its modified blood coagulation factor X. VarmX thinks the candidate can restore blood clotting in patients taking anticoagulants. Statement

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.